Medtronic (NYSE:MDT) today announced a new real-world retrospective analysis highlighting positive outcomes with its MiniMed 780G. The medtech giant’s Diabetes business, which recently took the next step toward becoming a standalone public company called MiniMed through an IPO, said MiniMed 780G achieved American Diabetes Association (ADA)-recommended goals for time-in-range (TIR), even on days when mealtime […]
Medtronic
The top diabetes tech stories of 2025
As the year comes to a close, it’s time to look back at the numerous innovations across the diabetes technology industry in 2025. Once again, continuous glucose monitors (CGMs) and automated insulin delivery systems took most of the headlines, as the leaders in the space keep building on their platforms while challengers continue to enter […]
Medtronic Diabetes unit MiniMed files for IPO
Medtronic (NYSE:MDT) announced today that its MiniMed Diabetes business filed with the SEC for a proposed initial public offering (IPO). The medtech giant said MiniMed filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC). It expects to complete the separation from Medtronic through a series of capital markets transactions. […]
Medtronic rolls out MiniMed campaign for launch with Instinct sensor made by Abbott
Medtronic (NYSE:MDT) announced the launch of its “Own It” campaign for the rollout of its MiniMed 780G system and Instinct sensor made by Abbott. The campaign aims to bring awareness to the now available system that “works quietly in the background” while people with type 1 diabetes can go about their daily lives. Medtronic (soon […]
Medtronic studies highlight MiniMed 780G’s cost-effectiveness
Medtronic (NYSE: MDT) today announced new data demonstrating the health economic benefits of its MiniMed 780G system. Findings highlighted the advanced hybrid closed-loop automated insulin delivery system’s benefits compared to the standard of care using multiple daily injections (MDI) with intermittently scanned continuous glucose monitoring (isCGM). MiniMed 780G, Medtronic’s latest-generation automated insulin delivery system, provides real-time […]
Medtronic has a new head of investor relations, former head to join Diabetes spin-off MiniMed
![Medtronic named Ingrid Goldberg (right) as its new head of investor relations. Ryan Weispfenning (left) will leave to lead investor relations for MiniMed. [Images from LinkedIn]](https://www.drugdeliverybusiness.com/wp-content/uploads/2025/12/Medtronic-VP-Head-of-investor-relations-Ryan-Weispfenning-MiniMed-Ingrid-Goldberg-150x86.jpg)
Medtronic (NYSE: MDT) announced today that it named Ingrid Goldberg as its new VP and head of investor relations (IR). Goldberg’s appointment comes as Ryan Weispfenning, who previously held that role, elected to join the company’s Diabetes business and lead the IR function for the unit as it continues to work toward a separation from […]
Medtronic begins full commercial rollout of MiniMed 780G with Instinct sensor made by Abbott
Medtronic (NYSE:MDT) today announced the full U.S. launch for its Instinct sensor, made by Abbott, paired with the MiniMed 780G pump. The medtech giant’s diabetes unit — one of the largest diabetes tech businesses in the world — won FDA clearance for its SmartGuard algorithm as an interoperable automated glycemic controller (iAGC) earlier this year, enabling […]
Medtronic Diabetes to submit patch pump to FDA by fall 2026, separation remains on track
Medtronic officials today said the planned separation of its Diabetes business (MiniMed) remains on track, with future offerings also on the horizon. On the company’s second-quarter earnings call, CFO Thierry Piéton outlined the expected timelines for the Diabetes business, following another quarter of significant growth. Global Diabetes revenues grew 10.3% year over year, despite a […]
What diabetes tech companies are doing on World Diabetes Day 2025
Once again, World Diabetes Day, celebrated on Nov. 14 every year, has come around, highlighting new initiatives in the diabetes tech space. The date marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. It also lands during the American Diabetes Association’s National Diabetes Awareness Month. […]
The top CGM stories of 2025
Millions of people worldwide are looking for ways to manage their diabetes. That’s where the continuous glucose monitor (CGM) comes in. The CGM market is expected to experience substantial, double-digit percentage growth over the next five years, reaching nearly $29 billion by 2030. Market leaders Abbott and Dexcom continue to establish their hold on the […]
